Drug Profile
Diphenhydramine/trimethobenzamide
Alternative Names: Trimethobenzamide/diphenhydramineLatest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Multi-Corp International
- Developer Compass Point Research; NDA Partners
- Class Antiallergics; Antiemetics; Antimigraines; Antipruritics; Sedating antihistamines
- Mechanism of Action Histamine H1 receptor antagonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Migraine
Most Recent Events
- 28 May 2019 No recent reports of development identified for research development in Migraine in USA (Parenteral, Injection)
- 21 Jan 2016 MultiCorp International receives detailed response letter from the FDA for development of diphenhydramine/trimethobenzamide in Migraine
- 08 Apr 2015 MultiCorp International collaborates with Compass Point and NDA Partners to develop diphenhydramine/trimethobenzamide for the treatment of migraine